Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 89 of 1,261
  1. US 12109190

    Urolithins as immune response enhancers

    Amazentis SA Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  2. US 12109185

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  3. US 12109231

    Treatment of neurodegenerative disease with sodium chlorite

    The Regents of the University of California Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  4. US 12108745

    Rat model of IgA nephropathy induced with a multimeric recombinant IgA fragment

    Northwestern University Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  5. US 12109225

    Methods for potentiating cancer treatment using ionizing radiation

    GLYCOMIRA THERAPEUTICS, INC. Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  6. US 12109229

    Treatment of neurodegenerative disease with sodium chlorite

    The Regents of the University of California Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  7. US 12110502

    Models of tauopathy

    REGENERON PHARMACEUTICALS, INC. Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  8. US 12110343

    Anti-plasma kallikrein antibodies

    Takeda Pharmaceutical Company Limited Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  9. US 12110315

    Fish-derived peptidoglycan recognition protein mutant and application thereof

    OCEAN UNIVERSITY OF CHINA Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  10. US 12110520

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  11. US 12109296

    Peptide exhibiting wrinkle-improving activity and uses thereof

    CAREGEN CO., LTD. Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  12. US 12110492

    RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  13. US 12109196

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  14. US 12110334

    Neutralizing antibodies to the Ξ±vΞ²8 integrin complex for immunotherapy

    The Regents of the University of California Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  15. US 12109198

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Fulcrum Therapeutics, Inc. Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  16. US 12110491

    Selective reduction of allelic variants

    Ionis Pharmaceuticals, Inc. Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  17. US 12109236

    Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function

    Regents of the University of Minnesota Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  18. US 12109239

    Methods for production of human hemogenic endothelial cells from pluripotent stem cells and compositions thereof

    Astellas Institute for Regenerative Medicine Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  19. US 12110344

    Antibodies that bind to cis and uses thereof

    DIANTHUS THERAPEUTICS OPCO, INC. Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  20. US 12109258

    Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections

    Inovio Pharmaceuticals, Inc. Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  21. US 12109228

    Treatment of neurodegenerative disease with sodium chlorite

    The Regents of the University of California Β· Granted Oct 8, 2024 Β· Expires Oct 3, 2044

    granted
  22. IT 202300006237

    COMPOSIZIONI NUTRACEUTICHE PER IL TRATTAMENTO O PREVENZIONE DI DISORDINI CONNESSI ALLA TRIMETILAMINURIA.

    ALFASIGMA SPA [IT] Β· Granted Oct 6, 2024 Β· Expires Oct 1, 2044

    granted
  23. PT 3721882

    TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] Β· Granted Oct 4, 2024 Β· Expires Sep 29, 2044

    granted
  24. WO 2024200854

    ANTICORPS DE LIAISON AUX ALLERGÈNES APPROPRIΓ‰S POUR TRAITER DES ALLERGIES AU POLLEN D'ARBRE

    ALK ABELLO AS [DK] Β· Granted Oct 3, 2024 Β· Expires Sep 28, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.